Venetoclax and Bomedemstat in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Status:
Not yet recruiting
Trial end date:
2025-11-15
Target enrollment:
Participant gender:
Summary
This study aims to learn about the safety, tolerability, and different dose levels' safety
profiles of Venetoclax and Bomedemstat (VenBom) combination therapy in participants with
relapsed or refractory acute myeloid leukemia.